This page is part of the FHIR Specification (v5.0.0: R5 - STU). This is the current published version. For a full list of available versions, see the Directory of published versions . Page versions: R5 R4B R4
Clinical Decision Support Work Group | Maturity Level: N/A | Standards Status: Informative | Compartments: No defined compartments |
This is the narrative for the resource. See also the XML, JSON or Turtle format. This example conforms to the profile PlanDefinition.
Generated Narrative: PlanDefinition
Resource PlanDefinition "opioidcds-07"
url: http://hl7.org/fhir/ig/opioid-cds/PlanDefinition/opioidcds-07
identifier: id: urn:oid:2.16.840.1.113883.4.642.11.6, id: cdc-opioid-guidance (use: OFFICIAL)
version: 0.1.0
name: Cdcopioid07
title: CDC Opioid Prescribing Guideline Recommendation #7
type: ECA Rule (PlanDefinitionType#eca-rule)
status: draft
date: 2018-03-19
publisher: Centers for Disease Control and Prevention (CDC)
description: Clinicians should evaluate benefits and harms with patients within 1 to 4 weeks of starting opioid therapy for chronic pain or of dose escalation. Clinicians should evaluate benefits and harms of continued therapy with patients every 3 months or more frequently.
- | Code | Value[x] |
* | Clinical Focus (Details: http://terminology.hl7.org/CodeSystem/usage-context-type code focus = 'Clinical Focus', stated as 'Clinical Focus') | Medication requested (situation) (SNOMED CT#182888003) |
* | Clinical Focus (Details: http://terminology.hl7.org/CodeSystem/usage-context-type code focus = 'Clinical Focus', stated as 'Clinical Focus') | Chronic pain (finding) (SNOMED CT#82423001) |
jurisdiction: United States of America (ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code#US)
purpose: CDC’s Guideline for Prescribing Opioids for Chronic Pain is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.
usage: If benefits do not outweigh harms of continued opioid therapy, clinicians should optimize other therapies and work with patients to taper opioids to lower dosages or to taper and discontinue opioids.
copyright: © CDC 2016+.
topic: Opioid Prescribing ()
author: Kensaku Kawamoto, MD, PhD, MHS: , Bryn Rhodes: , Floyd Eisenberg, MD, MPH: , Robert McClure, MD, MPH:
relatedArtifact
type: documentation
display: CDC guideline for prescribing opioids for chronic pain
document
relatedArtifact
type: documentation
display: MME Conversion Tables
document
library: http://example.org/fhir/Library/opioidcds-recommendation-07
action
title: Existing patient should be evaluated for risk of continued opioid therapy.
description: Checking if the trigger prescription meets the inclusion criteria for recommendation #7 workflow.
documentation
type: documentation
document
Triggers
- Type Name * named-event medication-prescribe condition
kind: applicability
Expressions
- Description Language Expression * Check whether the existing patient, without an end of life condition or risk assessment in the past 90 days, has taken an opioid-with-abuse-potential for 7 of the past 10 days or 63 of the past 90 days. text/cql Inclusion Criteria groupingBehavior: visual-group
selectionBehavior: exactly-one
dynamicValue
path: action.title
Expressions
- Language Expression * text/cql Get Summary dynamicValue
path: action.description
Expressions
- Language Expression * text/cql Get Detail dynamicValue
path: action.extension
Expressions
- Language Expression * text/cql Get Indicator Actions
- Description * Will schedule assessment of risk for opioid use for the patient * Risk of overdose carefully considered and outweighed by benefit; snooze 3 mo * N/A - see comment; snooze 3 mo
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.